BREAKING NEWS
Source: Hong Kong Baptist University  Jan 19, 2019  3 years ago
Killing tumours by targeting their viral DNA
Killing tumours by targeting their viral DNA
Source: Hong Kong Baptist University  Jan 19, 2019  3 years ago
Epstein-Barr virus infects more than 95 percent of people, usually without symptoms. But sometimes its persistence in cells can lead to tumor formation. Now, researchers from Hong Kong and the UK have developed a fluorescing, molecular-sized probe, called L2P4, which can inhibit Epstein-Barr-related tumor growth while allowing researchers to see the targeted tumor cells.

Killing tumours by targeting their viral DNA
Epstein-Barr virus infects more than 95% of people, usually without symptoms. But sometimes its persistence in cells can lead to tumour formation.
Copyright : Wikimedia commons


A team led by chemist Gary Ka-leung Wong from Hong Kong Baptist University developed the probe, which is formed of a nucleus-penetrating peptide linked to a fluorescent chemical compound. L2P4 targets a viral protein, called EBNA1, which is crucial for maintaining the Epstein-Barr virus (EBV) genome inside tumors.

The team tested the probe in EBV-positive tumor cells cultured in petri dishes and in EBV-positive tumors grafted into mice. They found that the peptide was only minimally toxic to cells that did not contain the virus, but that it became more toxic to EBV-positive tumor cells the higher the dose. Also, injecting L2P4 into EBV-positive tumors grafted into mice drastically reduced tumor size by 93 percent.

L2P4 works by disrupting the function of the viral protein EBNA1, interfering with the replication of EBV's genome in tumor cells, as well as reducing tumor cell stability.

But further investigations are needed. The researchers injected L2P4 directly into tumors, but localized tumors are already treated effectively by surgical removal or radiation. Injecting the probe into the body's general circulation could lead to an immune response   with a subsequent rapid reduction in its levels, preventing effective delivery to tumor cells.

Still, the probe is a promising target as a future tumor therapy. Its ability to fluoresce in EBV-positive tumor cells also means it could potentially be used in cancer imaging.

The team next plans to map intracellular zinc ions in EBV-infected cells. Zinc is involved in the regulation of EBNA1. The researchers would like to investigate adding a molecule that binds zinc to their probe to enhance its therapeutic effectiveness.

More information: Lijun Jiang et al. EBNA1-targeted probe for the imaging and growth inhibition of tumours associated with the Epstein–Barr virus, Nature Biomedical Engineering(2017). DOI: 10.1038/s41551-017-0042

MOST READ

Aug 13, 2020  2 years ago
Source: Supplements For COVID-19
Feb 05, 2020  2 years ago
Source : Thailand Medical news

FROM STEM CELL THERAPIES

LATEST ON MED NEWS